FGF22-IN-1 is a potential CD4 N-terminal immunoglobulin variable region-like domain (CD4 D1) inhibitor.

JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b+ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals.

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.